Looking deeper into the findings of DARE-19: Failure or an open door to future success?
作者信息
Koufakis Theocharis, Maltese Giuseppe, Metallidis Symeon, Zebekakis Pantelis, Kotsa Kalliopi
机构信息
Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece.
Department of Diabetes and Endocrinology, Epsom & St Helier University Hospitals, Surrey SM5 1AA, UK; Unit for Metabolic Medicine, Cardiovascular Division, Faculty of Life Sciences & Medicine, King's College, London WC2R 2LS, UK.
出版信息
Pharmacol Res. 2021 Nov;173:105872. doi: 10.1016/j.phrs.2021.105872. Epub 2021 Sep 4.
Abstract
摘要
相似文献
1
Looking deeper into the findings of DARE-19: Failure or an open door to future success?
Pharmacol Res. 2021 Nov;173:105872. doi: 10.1016/j.phrs.2021.105872. Epub 2021 Sep 4.
2
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
Diabetes Obes Metab. 2021 Apr;23(4):886-896. doi: 10.1111/dom.14296. Epub 2021 Jan 19.
3
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Diabetes Endocrinol. 2021 Sep;9(9):586-594. doi: 10.1016/S2213-8587(21)00180-7. Epub 2021 Jul 21.
4
Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors.
Int J Med Sci. 2018 Jun 13;15(9):937-943. doi: 10.7150/ijms.22224. eCollection 2018.
5
Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma.
Med Sci Monit. 2017 Aug 1;23:3737-3745. doi: 10.12659/msm.902530.
6
Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.
Cardiovasc Diabetol. 2019 Oct 4;18(1):129. doi: 10.1186/s12933-019-0938-6.
7
Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin-angiotensin-aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study.
Mol Biol Rep. 2022 Mar;49(3):2321-2324. doi: 10.1007/s11033-022-07183-w. Epub 2022 Jan 31.
8
The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.
Intern Med. 2018 Aug 1;57(15):2147-2156. doi: 10.2169/internalmedicine.0701-17. Epub 2018 Mar 30.
9
Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
Diabetes Obes Metab. 2018 Jan;20(1):224-227. doi: 10.1111/dom.13057. Epub 2017 Aug 8.
10
Effect of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on gluconeogenesis in proximal renal tubules.
Diabetes Obes Metab. 2020 Mar;22(3):373-382. doi: 10.1111/dom.13905. Epub 2019 Dec 16.
引用本文的文献
1
Why have SGLT2 Inhibitors Failed to Achieve the Desired Success in COVID-19?
Curr Pharm Des. 2024;30(15):1149-1156. doi: 10.2174/0113816128300162240322075423.
2
Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19.
Biomedicines. 2022 Oct 19;10(10):2624. doi: 10.3390/biomedicines10102624.
3
From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients.
Drugs. 2022 Jun;82(9):949-955. doi: 10.1007/s40265-022-01730-2. Epub 2022 Jun 9.
4
Metformin Use in Relation to Clinical Outcomes and Hyperinflammatory Syndrome Among COVID-19 Patients With Type 2 Diabetes: A Propensity Score Analysis of a Territory-Wide Cohort.
Front Endocrinol (Lausanne). 2022 Mar 7;13:810914. doi: 10.3389/fendo.2022.810914. eCollection 2022.
5
Hospital management of hyperglycemia in the context of COVID-19: evidence-based clinical considerations.
Diabetol Metab Syndr. 2022 Mar 4;14(1):37. doi: 10.1186/s13098-022-00808-x.
本文引用的文献
1
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Diabetes Endocrinol. 2021 Sep;9(9):586-594. doi: 10.1016/S2213-8587(21)00180-7. Epub 2021 Jul 21.
2
Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases.
Int J Clin Pharm. 2021 Jun;43(3):764-767. doi: 10.1007/s11096-021-01256-9. Epub 2021 Mar 9.
3
Anti-inflammatory potential of Empagliflozin.
Inflammopharmacology. 2021 Apr;29(2):573-576. doi: 10.1007/s10787-021-00797-9. Epub 2021 Mar 17.
4
Intestinal SGLT1 as a therapeutic target in COVID-19-related diabetes: A "two-edged sword" hypothesis.
Br J Clin Pharmacol. 2021 Oct;87(10):3643-3646. doi: 10.1111/bcp.14800. Epub 2021 Mar 8.
5
COVID-19 and Excess All-Cause Mortality in the US and 18 Comparison Countries.
JAMA. 2020 Nov 24;324(20):2100-2102. doi: 10.1001/jama.2020.20717.
6
New Agents in Development for Sepsis: Any Reason for Hope?
Drugs. 2020 Nov;80(17):1751-1761. doi: 10.1007/s40265-020-01402-z.
7
Empagliflozin suppresses inflammation and protects against acute septic renal injury.
Inflammopharmacology. 2021 Feb;29(1):269-279. doi: 10.1007/s10787-020-00732-4. Epub 2020 Jun 20.
Zotero 插件